Roivant Sciences Ltd.
10.96
0.22 (2.05%)
At close: Jan 14, 2025, 3:59 PM
10.72
-2.14%
After-hours Jan 14, 2025, 04:38 PM EST
undefined%
Bid 10.61
Market Cap 7.97B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 5.54
PE Ratio (ttm) 1.98
Forward PE n/a
Analyst Buy
Ask 11.49
Volume 4,675,366
Avg. Volume (20D) 4,694,301
Open 10.82
Previous Close 10.74
Day's Range 10.81 - 11.25
52-Week Range 9.69 - 13.05
Beta undefined

About ROIV

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2020
Employees 908
Stock Exchange NASDAQ
Ticker Symbol ROIV

Analyst Forecast

According to 8 analyst ratings, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 64.31% from the latest price.

Buy 87.50%
Hold 12.50%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Roivant Sciences Ltd. is scheduled to release its earnings on Feb 11, 2025, before market opens.
Analysts project revenue of $5.00M, reflecting a -86.54% YoY shrinking and earnings per share of -0.22, making a 4.76% increase YoY.
5 months ago · Source
+6.69%
Roivant Sciences shares are trading higher after t... Unlock content with Pro Subscription
9 months ago · Source
+4.7%
Roivant Sciences shares are trading higher after the company announced results from its NEPTUNE Phase 2 study of brepocitinib. The company's board also authorized a share repurchase program of up to $1.5 billion, including the repurchase of all 71.3 million shares held by Sumitomo Pharma.